Study on the clinical efficacy of Shenmai injection in the treatment of coronary heart disease and chronic heart failure
Objective To investigate the clinical efficacy of Shenmai injection in the treatment of coronary heart disease and chronic heart failure(CHD-CHF)and its effects on left heart function,the levels of serum factors and serum coagulatin indicators.Methods A total of 118 patients with CHD-CHF were selected and divided into the observation group and the control group according to random number table method,with 59 cases in each group.The control group received treatment with Atorvastatin calcium tablets,and the observation group received combined treatment with Shenmai injection on the basis of the treatment of the control group.Both groups were treated for 1 month.The clinical efficacy,left heart function,changes of the levels of serum factors and coagulation indexes before and after treatment,and incidence of adverse reactions during treatment were compared between two groups.Results The total effective rate of clinical efficacy in the observation group(91.53％,54/59)was higher than that in the control group(72.88％,43/59)(P＜0.05).After treatment,compared with before treatment,the serum levels of brain natriuretic peptide(BNP),neuropeptide Y(NPY),creatine kinase-MB(CK-MB),granular membrane protein(GMP-140),von Willebrand factor(vWF),fibrinogen(FIB)and D-Dimer(D-D),left ventricular end-systolic diameter(LVESD),and left ventricular end diastolic diameter(LVEDD)in both groups decreased,and the observation group was lower than the control group(P＜0.05).After treatment,compared with before treatment,left ventricular ejection fraction(LVEF)in both groups increased,and the observation group was higher than the control group(P＜0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P＜0.05).Conclusion Shenmai injection combined with Atorvastatin calcium tablets can reduce serum levels of BNP,NPY and CK-MB,regulate the levels of the coagulation indicators,and improve left heart function in patients with CHD-CHF.This therapy has definite efficacy and high safety.
万方数据
维普
